MicroRNA‑149 inhibits cancer cell malignant phenotype by regulating Akt1 in C4‑2 CRPC cell line

Zhao,Jiahui; Li,Qiankun; Feng,Bingfu; Wei,Dechao; Han,Yili; Li,Mingchuan; Wang,Yongxing; Luo,Yong; Jiang,Yongguang

doi:10.3892/or.2021.8209

MicroRNA‑149 inhibits cancer cell malignant phenotype by regulating Akt1 in C4‑2 CRPC cell line

Authors:
- Jiahui Zhao
- Qiankun Li
- Bingfu Feng
- Dechao Wei
- Yili Han
- Mingchuan Li
- Yongxing Wang
- Yong Luo
- Yongguang Jiang
View Affiliations

Affiliations: Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Chaoyang, Beijing 100029, P.R. China
Published online on: October 25, 2021 https://doi.org/10.3892/or.2021.8209
Article Number: 258
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is an androgen‑dependent disease. Androgen receptor (AR) has a crucial role in the development and progression of PCa. Recently, several microRNAs (miRNAs/miRs) involved in AR regulation have been associated with castration‑resistant prostate cancer (CRPC), the terminal stage of PCa. Nevertheless, the precise mechanism remains unclear. The present study aimed to identify a novel miR‑149 regulatory network and potential therapeutic target for CRPC. It was found that ectopic expression of miR‑149 mimic could inhibit AR expression, repress epithelial‑mesenchymal transition, induce cell cycle arrest and apoptosis in CRPC cell line C4‑2, whereas the miR‑149 inhibitor exerted the opposite effects. Furthermore, it was also revealed that miR‑149 could reduce the functional activity of the PI3K/Akt1 signaling pathway by targeting Akt1 protein, the key regulatory factor of the PI3K/Akt1 signaling pathway. Knockdown of Akt1 by short hairpin RNA increased apoptosis, reduced proliferation, and restrained migration and invasion in CRPC cells, with the effect of AR inhibition. In conclusion, these results revealed that miR‑149 acts as a tumor suppressor in CRPC cell line C4‑2 and restrains its progression through the AR signaling pathway by targeting Akt1. The miR‑149/Akt1/AR regulatory pathway may represent a novel PCa therapeutic target.

View Figures

View References

1	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ritch C and Cookson M: Recent trends in the management of advanced prostate cancer. F1000Res. 7:15132018. View Article : Google Scholar : PubMed/NCBI
3	Dai C, Heemers H and Sharifi N: Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 7:a0304522017. View Article : Google Scholar : PubMed/NCBI
4	Teo MY, Rathkopf DE and Kantoff P: Treatment of advanced prostate cancer. Annu Rev Med. 70:479–499. 2019. View Article : Google Scholar : PubMed/NCBI
5	Bastos D and Antonarakis E: CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Rev Mol Diagn. 18:155–163. 2018. View Article : Google Scholar : PubMed/NCBI
6	Shorning BY, Dass MS, Smalley MJ and Pearson HB: The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 21:45072020. View Article : Google Scholar : PubMed/NCBI
7	Edlind MP and Hsieh AC: PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lee SH, Johnson D, Luong R and Sun Z: Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells. J Biol Chem. 290:2759–2768. 2015. View Article : Google Scholar : PubMed/NCBI
9	Wang K, Ruan H, Xu T, Liu L, Liu D, Yang H, Zhang X and Chen K: Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. Onco Targets Ther. 11:3167–3178. 2018. View Article : Google Scholar : PubMed/NCBI
10	Rafiei S, Gui B, Wu J, Liu XS, Kibel AS and Jia L: Targeting the MIF/CXCR7/AKT signaling pathway in castration-resistant prostate cancer. Mol Cancer Res. 17:263–276. 2019. View Article : Google Scholar : PubMed/NCBI
11	He Y, Yu D, Zhu L, Zhong S, Zhao J and Tang J: miR-149 in human cancer: A systemic review. J Cancer. 9:375–388. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xie Z, Xu J, Peng L, Gao Y, Zhao H and Qu Y: miR-149 promotes human osteocarcinoma progression via targeting bone morphogenetic protein 9 (BMP9). Biotechnol Lett. 40:47–55. 2018. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Ju K, Wang W, Liu Z, Xie H, Jiang Y, Jiang G, Lu J, Dong Z and Tang F: Dinitrosopiperazine-decreased PKP3 through upregulating miR-149 participates in nasopharyngeal carcinoma metastasis. Mol Carcinog. 57:1763–1779. 2018. View Article : Google Scholar : PubMed/NCBI
14	Ma J, Wei H, Li X and Qu X: hsa-miR-149-5p suppresses prostate carcinoma malignancy by suppressing RGS17. Cancer Manag Res. 13:2773–2783. 2021. View Article : Google Scholar : PubMed/NCBI
15	Wang C, Ding T, Yang D, Zhang P, Hu X, Qin W and Zheng J: The lncRNA OGFRP1/miR-149-5p/IL-6 axis regulates prostate cancer chemoresistance. Pathol Res Pract. 224:1535352021. View Article : Google Scholar : PubMed/NCBI
16	Fujii T, Shimada K, Tatsumi Y, Fujimoto K and Konishi N: Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. 456:183–189. 2015. View Article : Google Scholar : PubMed/NCBI
17	Chen Y, Zhao J, Luo Y, Wang Y and Jiang Y: Downregulated expression of miRNA-149 promotes apoptosis in side population cells sorted from the TSU prostate cancer cell line. Oncol Rep. 36:2587–2600. 2016. View Article : Google Scholar : PubMed/NCBI
18	Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer. 57:406–412. 1994. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Odero-Marah V, Hawsawi O, Henderson V and Sweeney J: Epithelial-mesenchymal transition (EMT) and prostate cancer. Adv Exp Med Biol. 1095:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zhi Y, Zhou H, Mubalake A, Chen Y, Zhang B, Zhang K, Chu X and Wang R: Regulation and functions of MicroRNA-149 in human cancers. Cell Prolif. 51:e124652018. View Article : Google Scholar : PubMed/NCBI
22	Zhang Y, Guo X, Xiong L, Yu L, Li Z, Guo Q, Li Z, Li B and Lin N: Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Mol Cancer. 13:2532014. View Article : Google Scholar : PubMed/NCBI
23	Fogli S, Polini B, Carpi S, Pardini B, Naccarati A, Dubbini N, Lanza M, Breschi MC, Romanini A and Nieri P: Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol. 39:10104283177016462017. View Article : Google Scholar : PubMed/NCBI
24	Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017. View Article : Google Scholar : PubMed/NCBI
25	Chen H, Zhou L, Wu X, Li R, Wen J, Sha J and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 21:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
26	Nóbrega M, Cilião HL, Souza MF, Souza MR, Serpeloni JM, Fuganti PE and Cólus IMS: Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer. Genet Mol Biol. 43:e201803292020. View Article : Google Scholar : PubMed/NCBI
27	Hu M, Zhu S, Xiong S, Xue X and Zhou X: MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review). Oncol Rep. 41:1439–1454. 2019.PubMed/NCBI
28	Ghafouri-Fard S, Shoorei H and Taheri M: miRNA profile in ovarian cancer. Exp Mol Pathol. 113:1043812020. View Article : Google Scholar : PubMed/NCBI
29	Wise HM, Hermida MA and Leslie NR: Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 131:197–210. 2017. View Article : Google Scholar : PubMed/NCBI
30	Chen J, Xu Y, Tao L, Pan Y, Zhang K, Wang R, Chen LB and Chu X: miRNA-26a contributes to the acquisition of malignant behaviors of doctaxel-resistant lung adenocarcinoma cells through targeting EZH2. Cell Physiol Biochem. 41:583–597. 2017. View Article : Google Scholar : PubMed/NCBI
31	Niu Y, Tang G, Wu X and Wu C: LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis. Saudi J Gastroenterol. 26:194–203. 2020. View Article : Google Scholar : PubMed/NCBI
32	Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG and Sun BM: MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol. 25:871–881. 2012. View Article : Google Scholar : PubMed/NCBI
33	De Nunzio C, Presicce F, Giacinti S, Bassanelli M and Tubaro A: Castration-resistance prostate cancer: What is in the pipeline? Minerva Urol Nefrol. 70:22–41. 2018.PubMed/NCBI
34	Galletti G, Leach BI, Lam L and Tagawa ST: Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 57:16–27. 2017. View Article : Google Scholar : PubMed/NCBI
35	James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, et al: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 377:338–351. 2017. View Article : Google Scholar : PubMed/NCBI
36	Yan Y and Huang H: Interplay among PI3K/AKT, PTEN/FOXO and AR signaling in prostate cancer. Adv Exp Med Biol. 1210:319–331. 2019. View Article : Google Scholar : PubMed/NCBI